We caught up with Prof Joachim Ehrlich (Head of Cardiology and Electrophysiology, St Josefs-Hospital, Wiesbaden, Germany) on the recent studies in the use of pulmonary vein isolation in patients with atrial fibrillation and heart failure and the advantages of cryoballoon ablation compared with radiofrequency ablation. He also gave us an overview of their recent cohort study and its findings.
- What have recent studies taught us about the utility of pulmonary vein isolation in patients with atrial fibrillation and heart failure? (0.18)
- What are the advantages of cryoballoon ablation compared with radiofrequency ablation in the treatment of atrial fibrillation? (2.15)
- Could you give us a brief overview of your cohort study and its findings? (3.12)
- What are the limitations of cryoballoon ablation in this patient population? (4.26)
- What will be the impact of your findings on clinical practice? (5.06)
Speaker’s disclosures: Professor Joachim Ehrlich has nothing to declare in relation to this video interview.
Support: Commissioned, edited and funded by Touch Medical Media.
Filmed during a remote video call with Professor Joachim Ehrlich, September 2020.
Share this Video
Related Videos In Heart Failure
Anthony Tang, ACC 2021: Findings from the RAFT-AF Trial
It was a great pleasure to meet with Anthony Tang to discuss the RAFT-AF trial results investigating the safety and efficacy of catheter ablation-based rhythm control compared with rate control for the treatment of patients with atrial fibrillation and heart failure, presented at ACC 2021. Abstract Title: A Randomized Ablation-based atrial Fibrillation rhythm control versus […]
Michiel Rienstra and Bao-Oanh Nguyen, EHRA 2021 – Long-term Outcomes of the RACE 3 Trial
Professor Michiel Rienstra and Dr Bao-Oanh Nguyen (University Medical Center Groningen, Groningen, The Netherlands) gave us an overview of the RACE-3 study (NCT00877643) from the European Heart Rhythm Association (EHRA) Virtual Meeting 2021. Questions: What is the rationale for targeted therapy of underlying conditions in patients with persistent atrial fibrillation (AF) and mild to moderate […]
Hugh Calkins, AF Symposium 2021: Atrial Fibrillation and HFrEF and HFpEF
We spoke to Professor Hugh Calkins (Johns Hopkins Hospital, Baltimore, MD, USA) about atrial fibrillation and heart failure with reduced and preserved ejection fraction. Questions: What is the prevalence of atrial fibrillation (AF) in patients with heart failure (HF) and reduced (HFrEF) and preserved (HFpEF) ejection fraction? (0.13) What is the impact of AF on […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!